HRP20200195T1 - Antibiotske terapije na bazi peptida porijeklom od vodenog bivola - Google Patents
Antibiotske terapije na bazi peptida porijeklom od vodenog bivola Download PDFInfo
- Publication number
- HRP20200195T1 HRP20200195T1 HRP20200195TT HRP20200195T HRP20200195T1 HR P20200195 T1 HRP20200195 T1 HR P20200195T1 HR P20200195T T HRP20200195T T HR P20200195TT HR P20200195 T HRP20200195 T HR P20200195T HR P20200195 T1 HRP20200195 T1 HR P20200195T1
- Authority
- HR
- Croatia
- Prior art keywords
- group
- trp
- leu
- arg
- phe
- Prior art date
Links
- 241000030939 Bubalus bubalis Species 0.000 title 1
- 239000003910 polypeptide antibiotic agent Substances 0.000 title 1
- 238000002560 therapeutic procedure Methods 0.000 title 1
- 125000003275 alpha amino acid group Chemical group 0.000 claims 15
- 230000000845 anti-microbial effect Effects 0.000 claims 15
- 230000003115 biocidal effect Effects 0.000 claims 10
- 244000005700 microbiome Species 0.000 claims 10
- 108090000765 processed proteins & peptides Proteins 0.000 claims 10
- 239000003242 anti bacterial agent Substances 0.000 claims 7
- 239000004599 antimicrobial Substances 0.000 claims 6
- 238000000034 method Methods 0.000 claims 5
- 241000894006 Bacteria Species 0.000 claims 4
- 208000015181 infectious disease Diseases 0.000 claims 3
- 208000004396 mastitis Diseases 0.000 claims 3
- 241000194033 Enterococcus Species 0.000 claims 2
- 241000588722 Escherichia Species 0.000 claims 2
- 241000233866 Fungi Species 0.000 claims 2
- 241000606790 Haemophilus Species 0.000 claims 2
- 241000589516 Pseudomonas Species 0.000 claims 2
- 240000004808 Saccharomyces cerevisiae Species 0.000 claims 2
- 241000191940 Staphylococcus Species 0.000 claims 2
- 241000194017 Streptococcus Species 0.000 claims 2
- 239000003937 drug carrier Substances 0.000 claims 2
- 230000002401 inhibitory effect Effects 0.000 claims 2
- 241000588915 Klebsiella aerogenes Species 0.000 claims 1
- 241000588747 Klebsiella pneumoniae Species 0.000 claims 1
- 241000191967 Staphylococcus aureus Species 0.000 claims 1
- 241000193985 Streptococcus agalactiae Species 0.000 claims 1
- 241000194042 Streptococcus dysgalactiae Species 0.000 claims 1
- 241000194054 Streptococcus uberis Species 0.000 claims 1
- 241000186064 Trueperella pyogenes Species 0.000 claims 1
- 210000000481 breast Anatomy 0.000 claims 1
- 229940092559 enterobacter aerogenes Drugs 0.000 claims 1
- 238000000338 in vitro Methods 0.000 claims 1
- 230000000813 microbial effect Effects 0.000 claims 1
- 229940115920 streptococcus dysgalactiae Drugs 0.000 claims 1
- 229940115922 streptococcus uberis Drugs 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
- A01N37/00—Biocides, pest repellants or attractants, or plant growth regulators containing organic compounds containing a carbon atom having three bonds to hetero atoms with at the most two bonds to halogen, e.g. carboxylic acids
- A01N37/44—Biocides, pest repellants or attractants, or plant growth regulators containing organic compounds containing a carbon atom having three bonds to hetero atoms with at the most two bonds to halogen, e.g. carboxylic acids containing at least one carboxylic group or a thio analogue, or a derivative thereof, and a nitrogen atom attached to the same carbon skeleton by a single or double bond, this nitrogen atom not being a member of a derivative or of a thio analogue of a carboxylic group, e.g. amino-carboxylic acids
- A01N37/46—N-acyl derivatives
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
- A01N47/00—Biocides, pest repellants or attractants, or plant growth regulators containing organic compounds containing a carbon atom not being member of a ring and having no bond to a carbon or hydrogen atom, e.g. derivatives of carbonic acid
- A01N47/40—Biocides, pest repellants or attractants, or plant growth regulators containing organic compounds containing a carbon atom not being member of a ring and having no bond to a carbon or hydrogen atom, e.g. derivatives of carbonic acid the carbon atom having a double or triple bond to nitrogen, e.g. cyanates, cyanamides
- A01N47/42—Biocides, pest repellants or attractants, or plant growth regulators containing organic compounds containing a carbon atom not being member of a ring and having no bond to a carbon or hydrogen atom, e.g. derivatives of carbonic acid the carbon atom having a double or triple bond to nitrogen, e.g. cyanates, cyanamides containing —N=CX2 groups, e.g. isothiourea
- A01N47/44—Guanidine; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
- A01N63/00—Biocides, pest repellants or attractants, or plant growth regulators containing microorganisms, viruses, microbial fungi, animals or substances produced by, or obtained from, microorganisms, viruses, microbial fungi or animals, e.g. enzymes or fermentates
- A01N63/50—Isolated enzymes; Isolated proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/14—Drugs for genital or sexual disorders; Contraceptives for lactation disorders, e.g. galactorrhoea
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Zoology (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Pest Control & Pesticides (AREA)
- Agronomy & Crop Science (AREA)
- Environmental Sciences (AREA)
- Wood Science & Technology (AREA)
- Dentistry (AREA)
- Plant Pathology (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Gastroenterology & Hepatology (AREA)
- Toxicology (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Virology (AREA)
- Reproductive Health (AREA)
- Pregnancy & Childbirth (AREA)
- Gynecology & Obstetrics (AREA)
- Endocrinology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
Claims (21)
1. Antibiotski pripravak koji sadrži antibiotski peptid, naznačen time što peptid sadrži sintetičku aminokiselinsku sekvencu koja ima sekvencu prema SEQ ID NO: 4103:
Gly-X1-X2-X3-X1-X1-X1-Arg-X4-X1-X5-X6-X6-Gly pri čemu
X1 je izabran iz grupe od Leu ili Ile,
X2 je izabran iz grupe od Ala, Val, Leu ili Ile,
X3 je izabran iz grupe od Arg ili Trp,
X4 je izabran iz grupe od Trp, Ile ili Leu
X5 je izabran iz grupe od Phe ili Trp, i
X6 je izabran iz grupe od Phe, Trp ili Arg.
2. Antibiotski pripravak koji sadrži antibiotski peptid, naznačen time što peptid sadrži sintetičku aminokiselinsku sekvencu koja ima sekvencu prema SEQ ID NO: 4102:
Gly-X1-X2-X3-X1-X1-X1-Arg-X4-X1-X5-Arg-X6-Gly pri čemu
X1 je izabran iz grupe od Leu ili Ile,
X2 je izabran iz grupe od Ala, Val, Leu, Ile ili Pro,
X3 je izabran iz grupe od Arg ili Trp,
X4 je izabran iz grupe od Trp, Ile ili Leu
X5 je izabran iz grupe od Phe ili Trp, i
X6 je izabran iz grupe od Phe, Trp ili Arg.
3. Antibiotski pripravak koji sadrži antibiotski peptid, naznačen time što peptid sadrži:
a. prvu sintetičku aminokiselinsku sekvencu koja ima sekvencu prema SEQ ID NO: 4103:
Gly-X1-X2-X3-X1-X1-X1-Arg-X4-X1-X5-X6-X6-Gly pri čemu
X1 je izabran iz grupe od Leu ili Ile,
X2 je izabran iz grupe od Ala, Val, Leu ili Ile,
X3 je izabran iz grupe od Arg ili Trp,
X4 je izabran iz grupe od Trp, Ile ili Leu,
X5 je izabran iz grupe od Phe ili Trp, i
X6 je izabran iz grupe od Phe, Trp ili Arg;
b. drugu sintetičku aminokiselinsku sekvencu koja ima sekvencu prema SEQ ID NO: 4103:
Gly-X1-X2-X3-X1-X1-X1-Arg-X4-X1-X5-X6-X6-Gly pri čemu
X1 je izabran iz grupe od Leu ili Ile,
X2 je izabran iz grupe od Ala, Val, Leu ili Ile,
X3 je izabran iz grupe od Arg ili Trp,
X4 je izabran iz grupe od Trp, Ile, ili Leu,
X5 je izabran iz grupe od Phe ili Trp, i
X6 je izabran iz grupe od Phe, Trp ili Arg; i
c. veznu sekvencu, pri čemu vezna sekvenca operativno povezuje prvu aminokiselinsku sekvencu i drugu aminokiselinsku sekvencu.
4. Antimikrobni pripravak koji sadrži antibiotski peptid, naznačen time što peptid sadrži:
a. prvu sintetičku aminokiselinsku sekvencu koja ima sekvencu prema SEQ ID NO: 4102:
Gly-X1-X2-X3-X1-X1-X1-Arg-X4-X1-X5-Arg-X6-Gly pri čemu
X1 je izabran iz grupe od Leu ili Ile,
X2 je izabran iz grupe od Ala, Val, Leu, Ile ili Pro,
X3 je izabran iz grupe od Arg ili Trp,
X4 je izabran iz grupe od Trp, Ile ili Leu
X5 je izabran iz grupe od Phe ili Trp, i
X6 je izabran iz grupe od Phe ili Trp;
b. drugu sintetičku aminokiselinsku sekvencu koja ima sekvencu prema SEQ ID NO: 4102:
Gly-X1-X2-X3-X1-X1-X1-Arg-X4-X1-X5-Arg-X6-Gly pri čemu
X1 je izabran iz grupe od Leu ili Ile,
X2 je izabran iz grupe od Ala, Val, Leu, Ile ili Pro,
X3 je izabran iz grupe od Arg ili Trp,
X4 je izabran iz grupe od Trp, Ile ili Leu
X5 je izabran iz grupe od Phe ili Trp, i
X6 je izabran iz grupe od Phe ili Trp; i,
c. veznu sekvencu, pri čemu vezna sekvenca operativno povezuje prvu aminokiselinsku sekvencu i drugu aminokiselinsku sekvencu.
5. Antimikrobni pripravak koji sadrži antibiotski peptid, naznačen time što peptid sadrži:
a. prvu sintetičku aminokiselinsku sekvencu koja ima sekvencu prema SEQ ID NO: 4103:
Gly-X1-X2-X3-X1-X1-X1-Arg-X4-X1-X5-X6-X6-Gly pri čemu
X1 je izabran iz grupe od Leu ili Ile,
X2 je izabran iz grupe od Ala, Val, Leu ili Ile,
X3 je izabran iz grupe od Arg ili Trp,
X4 je izabran iz grupe od Trp, Ile ili Leu,
X5 je izabran iz grupe od Phe ili Trp, i
X6 je izabran iz grupe od Phe ili Trp;
b. drugu sintetičku aminokiselinsku sekvencu koja ima sekvencu prema SEQ ID NO: 4102:
Gly-X1-X2-X3-X1-X1-X1-Arg-X4-X1-X5-Arg-X6-Gly pri čemu
X1 je izabran iz grupe od Leu ili Ile,
X2 je izabran iz grupe od Ala, Val, Leu, Ile ili Pro,
X3 je izabran iz grupe od Arg ili Trp,
X4 je izabran iz grupe od Trp, Ile ili Leu,
X5 je izabran iz grupe od Phe ili Trp, i
X6 je izabran iz grupe od Phe ili Trp; i
c. veznu sekvencu, pri čemu vezna sekvenca operativno povezuje prvu aminokiselinsku sekvencu i drugu aminokiselinsku sekvencu.
6. Antimikrobni pripravak prema bilo kojem od patentnih zahtjeva 1 do 5, naznačen time što pripravak inhibira rast mikroorganizama.
7. Antimikrobni pripravak prema patentnom zahtjevu 6, naznačen time što su mikroorganizmi izabrani iz grupe koja se sastoji od bakterija, gljiva, kvasca, plijesni i njihovih kombinacija.
8. Antimikrobni pripravak prema patentnom zahtjevu 7, naznačen time što su bakterije izabrane iz grupe koja se sastoji od Pseudomonas, Escherichia, Staphylococcus, Streptococcus, Enterococcus, Mycobacteria, Haemophilus i njihovih kombinacija.
9. Antimikrobni pripravak prema bilo kojem od patentnih zahtjeva 1 do 8 koji dalje sadrži farmaceutski nosač.
10. Antimikrobni pripravak prema bilo kojem od patentnih zahtjeva 1 do 9, naznačen time što sintetička aminokiselinska sekvenca ima najmanje 85% identičnosti sekvence sa SEQ ID NO: 8.
11. In vitro postupak za inhibiciju rasta mikroorganizma koji sadrži dovođenje u kontakt mikroorganizma, tokom vremena i pod uvjetima koji su efikasni u inhibiciji rasta mikroorganizma, sa pripravkom prema bilo kojem od patentnih zahtjeva 1 do 10.
12. Postupak prema patentnom zahtjevu 11, naznačen time što je mikroorganizam izabran iz grupe koja se sastoji od bakterija, gljiva, kvasca, plijesni i njihovih kombinacija.
13. Postupak prema patentnom zahtjevu 12, naznačen time što bakterije su izabrane iz grupe koja se sastoji od Pseudomonas, Escherichia, Staphylococcus, Streptococcus, Enterococcus, Mycobacteria, Haemophilus i njihovih kombinacija.
14. Postupak prema patentnom zahtjevu 11 ili 12, naznačen time što je mikroorganizam izabran iz grupe koja se sastoji od Streptococcus agalactiae, Staphylococcus aureus, Enterobacter aerogenes, Klebsiella pneumoniae, Actinomyces pyogenes, Streptococcus uberis, Streptococcus dysgalactiae i njihovih kombinacija.
15. Postupak prema bilo kojem od patentnih zahtjeva 11 do 14, naznačen time što je rast mikroorganizma inhibiran za najmanje 10%.
16. Antimikrobni pripravak prema bilo kojem od patentnih zahtjeva 1 do 10, za uporabu u liječenju mikrobne infekcije.
17. Antimikrobni pripravak za uporabu prema patentnom zahtjevu 16, naznačen time što antibiotski pripravak dalje sadrži farmaceutski nosač.
18. Antimikrobni pripravak za uporabu prema patentnom zahtjevu 16 ili 17, naznačen time što navedeni antimikrobni pripravak inhibira rast mikroorganizma koji izaziva infekciju mastitis za najmanje 10%.
19. Antimikrobni pripravak prema bilo kojem od patentnih zahtjeva 1 do 10, za uporabu u liječenju mastitisa.
20. Antimikrobni pripravak za uporabu prema patentnom zahtjevu 19, naznačen time što antibiotski pripravak se primjenjuje na tkivo dojke subjekta.
21. Antimikrobni pripravak za uporabu prema patentnom zahtjevu 19 ili 20, naznačen time što navedeni antimikrobni pripravak inhibira rast mikroorganizma koji izaziva infekciju mastitis za najmanje 10%.
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462032737P | 2014-08-04 | 2014-08-04 | |
| US14/483,083 US9029319B1 (en) | 2014-08-04 | 2014-09-10 | Water buffalo derived peptide antibiotic therapies |
| US14/678,558 US9273097B2 (en) | 2014-08-04 | 2015-04-03 | Water buffalo derived peptide antibiotic therapies |
| US14/692,518 US9163064B1 (en) | 2014-08-04 | 2015-04-21 | Water buffalo derived monomeric peptides containing proline for antibiotic therapies |
| US14/750,709 US9701716B2 (en) | 2014-08-04 | 2015-06-25 | Water buffalo derived dimeric peptide containing proline for antibiotic therapies |
| EP15829088.2A EP3179855B1 (en) | 2014-08-04 | 2015-07-28 | Water buffalo derived peptide antibiotic therapies |
| PCT/US2015/042435 WO2016022335A1 (en) | 2014-08-04 | 2015-07-28 | Water buffalo derived peptide antibiotic therapies |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20200195T1 true HRP20200195T1 (hr) | 2020-08-07 |
Family
ID=53038201
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20200195TT HRP20200195T1 (hr) | 2014-08-04 | 2020-02-06 | Antibiotske terapije na bazi peptida porijeklom od vodenog bivola |
Country Status (20)
| Country | Link |
|---|---|
| US (4) | US9029319B1 (hr) |
| EP (1) | EP3179855B1 (hr) |
| JP (1) | JP6802148B2 (hr) |
| CN (1) | CN108064131A (hr) |
| AR (1) | AR101416A1 (hr) |
| AU (1) | AU2015298629B2 (hr) |
| BR (1) | BR112017002166B1 (hr) |
| CA (1) | CA2956778C (hr) |
| CY (1) | CY1122747T1 (hr) |
| DK (1) | DK3179855T3 (hr) |
| ES (1) | ES2770705T3 (hr) |
| HR (1) | HRP20200195T1 (hr) |
| HU (1) | HUE048461T2 (hr) |
| LT (1) | LT3179855T (hr) |
| MX (1) | MX2017001566A (hr) |
| PL (1) | PL3179855T3 (hr) |
| PT (1) | PT3179855T (hr) |
| RS (1) | RS59987B1 (hr) |
| SI (1) | SI3179855T1 (hr) |
| WO (1) | WO2016022335A1 (hr) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9029319B1 (en) | 2014-08-04 | 2015-05-12 | Centaur, Inc. | Water buffalo derived peptide antibiotic therapies |
| CN109553677B (zh) * | 2018-11-30 | 2021-12-14 | 东北农业大学 | 基于两栖类蛙源抗菌肽的衍生肽w8及其制备方法和应用 |
| EP4129064A4 (en) * | 2020-03-30 | 2023-12-13 | Anygen Co., Ltd. | NEW ANTIBACTERIAL PEPTIDE AND USE THEREOF |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1250355A1 (en) * | 2000-01-21 | 2002-10-23 | The Burnham Institute | Chimeric prostate-homing peptides with pro-apoptotic activity |
| US8202835B2 (en) | 2005-06-17 | 2012-06-19 | Yitzchak Hillman | Disease treatment via antimicrobial peptides or their inhibitors |
| DE102009007381A1 (de) * | 2009-01-29 | 2010-08-05 | Amp-Therapeutics Gmbh & Co. Kg | Antibiotische Peptide |
| ES2761835T3 (es) * | 2009-02-06 | 2020-05-21 | Technophage Investig E Desenvolvimento Em Biotecnologia Sa | Fagos antibacterianos, péptidos de fagos y métodos de uso de los mismos |
| US9029319B1 (en) * | 2014-08-04 | 2015-05-12 | Centaur, Inc. | Water buffalo derived peptide antibiotic therapies |
-
2014
- 2014-09-10 US US14/483,083 patent/US9029319B1/en active Active
-
2015
- 2015-04-03 US US14/678,558 patent/US9273097B2/en active Active
- 2015-04-21 US US14/692,518 patent/US9163064B1/en active Active
- 2015-06-25 US US14/750,709 patent/US9701716B2/en active Active
- 2015-07-28 PL PL15829088T patent/PL3179855T3/pl unknown
- 2015-07-28 BR BR112017002166-8A patent/BR112017002166B1/pt active IP Right Grant
- 2015-07-28 CN CN201580052880.XA patent/CN108064131A/zh active Pending
- 2015-07-28 MX MX2017001566A patent/MX2017001566A/es active IP Right Grant
- 2015-07-28 PT PT158290882T patent/PT3179855T/pt unknown
- 2015-07-28 JP JP2017506818A patent/JP6802148B2/ja active Active
- 2015-07-28 AU AU2015298629A patent/AU2015298629B2/en active Active
- 2015-07-28 SI SI201531086T patent/SI3179855T1/sl unknown
- 2015-07-28 DK DK15829088.2T patent/DK3179855T3/da active
- 2015-07-28 CA CA2956778A patent/CA2956778C/en active Active
- 2015-07-28 WO PCT/US2015/042435 patent/WO2016022335A1/en active Application Filing
- 2015-07-28 HU HUE15829088A patent/HUE048461T2/hu unknown
- 2015-07-28 LT LTEP15829088.2T patent/LT3179855T/lt unknown
- 2015-07-28 RS RS20200124A patent/RS59987B1/sr unknown
- 2015-07-28 EP EP15829088.2A patent/EP3179855B1/en active Active
- 2015-07-28 ES ES15829088T patent/ES2770705T3/es active Active
- 2015-08-04 AR ARP150102491A patent/AR101416A1/es unknown
-
2020
- 2020-02-06 HR HRP20200195TT patent/HRP20200195T1/hr unknown
- 2020-02-07 CY CY20201100121T patent/CY1122747T1/el unknown
Also Published As
| Publication number | Publication date |
|---|---|
| AU2015298629A1 (en) | 2017-02-16 |
| US20160031940A1 (en) | 2016-02-04 |
| US9701716B2 (en) | 2017-07-11 |
| JP2017533177A (ja) | 2017-11-09 |
| WO2016022335A1 (en) | 2016-02-11 |
| EP3179855A4 (en) | 2018-05-23 |
| HUE048461T2 (hu) | 2020-07-28 |
| PL3179855T3 (pl) | 2020-06-29 |
| US9163064B1 (en) | 2015-10-20 |
| JP6802148B2 (ja) | 2020-12-16 |
| ES2770705T3 (es) | 2020-07-02 |
| CA2956778A1 (en) | 2016-02-11 |
| PT3179855T (pt) | 2020-02-21 |
| BR112017002166B1 (pt) | 2022-08-16 |
| US20160031954A1 (en) | 2016-02-04 |
| EP3179855B1 (en) | 2019-11-20 |
| RS59987B1 (sr) | 2020-03-31 |
| MX2017001566A (es) | 2017-10-12 |
| US9029319B1 (en) | 2015-05-12 |
| CA2956778C (en) | 2021-10-26 |
| CN108064131A (zh) | 2018-05-22 |
| EP3179855A1 (en) | 2017-06-21 |
| LT3179855T (lt) | 2020-02-25 |
| CY1122747T1 (el) | 2021-03-12 |
| US9273097B2 (en) | 2016-03-01 |
| SI3179855T1 (sl) | 2020-04-30 |
| DK3179855T3 (da) | 2020-02-17 |
| AR101416A1 (es) | 2016-12-14 |
| NZ728651A (en) | 2021-11-26 |
| AU2015298629B2 (en) | 2019-03-07 |
| BR112017002166A2 (pt) | 2018-01-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Boparai et al. | Mini review on antimicrobial peptides, sources, mechanism and recent applications | |
| HRP20200195T1 (hr) | Antibiotske terapije na bazi peptida porijeklom od vodenog bivola | |
| WO2017049233A3 (en) | Lysin polypeptides active against gram-negative bacteria | |
| MX2020006098A (es) | Lisinas y sus derivados con actividad bactericida contra pseudomona aeruginosa, en la presencia de suero humano. | |
| RU2018102796A (ru) | Предотвращение, разрушение и обработка биопленки лизином бактериофага | |
| WO2018155813A3 (ko) | 엔테로코쿠스 패슘에 대하여 용균력을 가지는 신규한 항균단백질 efal-2 | |
| RU2018121290A (ru) | Комбинации лизина бактериофага и антибиотика против грам-положительных бактерий | |
| WO2010141760A3 (en) | Antimicrobial peptides | |
| JP2017519730A5 (hr) | ||
| BR112017008184A2 (pt) | composições e linhagem | |
| CA3010564A1 (en) | An antibacterial composition and a method of treating staphylococcal infections with the antibacterial composition | |
| WO2019045248A3 (ko) | 주름 개선 활성을 나타내는 펩타이드 및 이의 용도 | |
| MX2016010385A (es) | Agentes antibacterianos. | |
| WO2019077634A3 (en) | Therapeutic compositions of antimicrobial peptides | |
| WO2013041663A3 (de) | Modifizierte apidaecinderivate als antibiotische peptide | |
| JP2013539776A5 (hr) | ||
| BR112021022239A2 (pt) | Agentes e métodos antibacterianos | |
| JP2017533177A5 (hr) | ||
| WO2014130655A3 (en) | Compositions and methods to inactivate and/or reduce production of microbial toxins | |
| NZ610400A (en) | Antimicrobial protein | |
| MX366894B (es) | Composiciones antimicrobianas y métodos para su producción. | |
| WO2016132359A3 (en) | Antimicrobial peptides | |
| BR112017014225A2 (pt) | cultura biologicamente pura de lactobacillus reuteri, cepas lactobacillus reuteri, composição de uso de uma ou mais cepas de bactérias do ácido láctico, e da composição, e, método para administração tópica de cepas de bactérias do ácido láctico. | |
| WO2018231058A3 (en) | ANTIMICROBIAL PEPTIDES AND THEIR MIXTURES HAVING ANTIMICROBIAL ACTIVITY AGAINST NEGATIVE GRAM PATHOGENS | |
| WO2019059572A3 (ko) | 홍어 껍질 유래의 신규한 항균 펩타이드 및 이의 용도 |